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Abstract
The pathology of malaria is a consequence of the parasitaemia which develops through the cyclical asexual replication of
parasites in a patient’s red blood cells. Multiple parasite ligand-erythrocyte receptor interactions must occur for successful
Plasmodium invasion of the human red cell. Two major malaria ligand families have been implicated in these variable ligand-
receptor interactions used by Plasmodium falciparum to invade human red cells: the micronemal proteins from the
Erythrocyte Binding Ligands (EBL) family and the rhoptry proteins from the Reticulocyte binding Homolog (PfRH) family.
Ligands from the EBL family largely govern the sialic acid (SA) dependent pathways of invasion and the RH family ligands
(except for RH1) mediate SA independent invasion. In an attempt to dissect out the invasion inhibitory effects of antibodies
against ligands from both pathways, we have used EBA-175 and RH5 as model members of each pathway. Mice were
immunized with either region II of EBA-175 produced in Pichia pastoris or full-length RH5 produced by the wheat germ cell-
free system, or a combination of the two antigens to look for synergistic inhibitory effects of the induced antibodies. Sera
obtained from these immunizations were tested for native antigen recognition and for efficacy in invasion inhibition assays.
Results obtained show promise for the potential use of such hybrid vaccines to induce antibodies that can block multiple
parasite ligand-red cell receptor interactions and thus inhibit parasite invasion.
Citation: Ord RL, Rodriguez M, Yamasaki T, Takeo S, Tsuboi T, et al. (2012) Targeting Sialic Acid Dependent and Independent Pathways of Invasion in Plasmodium
falciparum. PLoS ONE 7(1): e30251. doi:10.1371/journal.pone.0030251
Editor: Thomas J. Templeton, Weill Cornell Medical College, United States of America
Received October 3, 2011; Accepted December 16, 2011; Published January 12, 2012
Copyright:  2012 Ord et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by National Institute of Allergy and Infectious Diseases/Division of Microbiology and Infectious Diseases (NIAID/DMID) contract
AI-N01-045210 to SAIC, which also provided the EBA-175 region II recombinant protein. This work was also supported in part by grants from the Ministry of
Education, Culture, Sports, Science and Technology (21249028, 23117008), and from the Ministry of Health, Labour, and Welfare, Japan (H21-Chikyukibo-ippan-
005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: clobo@nybloodcenter.org
Introduction
In Plasmodium falciparum, the causative agent of the most lethal
form of human malaria, the cyclical bursting and invasion of
erythrocytes is responsible for all the clinical manifestations of the
disease [1]. Continued survival of the parasite in the human host
requires successful invasion of merozoites into uninfected eryth-
rocytes. This is an active and sophisticated process, and requires
multiple steps of interaction among receptors on the red cell and
parasite ligands [2]. P. falciparum has developed the ability to
invade red cells using multiple parasite ligand-erythrocyte receptor
interactions that have become known as alternative invasion
pathways [3]. Various parasite proteins can fulfill similar roles in
the invasion process and hence any successful malaria vaccine will
have to target all alternative pathways of invasion.
Two major types of invasion pathways have been described in
P. falciparum: a sialic acid (SA) dependent pathway and a SA
independent pathway. Two families of parasite ligands have been
implicated in these invasion pathways. Proteins of the Erythrocyte
Binding Ligands (EBL) family are stored in the micronemes, after
production in the endoplasmic reticulum, and include EBA-175
[4], EBA-140 [5,6], EBA-181 [7,8] and EBL-1 [9]. Glycophorins
(GP) A [10], B [11,12] and C [13] have been identified as the
receptors to which EBA-175, EBL-1 and EBA-140 bind,
respectively. The receptor to which EBA-181 binds has yet to be
identified, but has been found to be neuraminidase and chy-
motrypsin sensitive, and trypsin resistant [7]. As the glycophorins
are the major sialylated proteins on the erythrocyte, these parasite
proteins largely govern the sialic acid (SA) dependent pathways of
invasion.
In contrast, the second family of parasite ligands that mediate
invasion are the P. falciparum reticulocyte binding protein-like
homologues (PfRHs), PfRH1, PfRH2a, PfRH2b, PfRH3, PfRH4,
and PfRH5, and these act largely through SA independent
pathways [14–16]. RH1 is an exception in this group as it has been
found to interact with erythrocytes in a sialic acid dependent
manner [17]. The erythrocyte receptors for these proteins remain
unknown, except for RH4, which has been found to adhere to
complement receptor 1 (CR1) [18].
During the process of invasion, merozoites are unprotected
within the blood stream. They are exposed to circulating host
immune factors and, in natural human populations, encounter a
heterogeneous population of erythrocyte surface proteins. Whilst
there is evidence that antibodies against native EBL and RH pro-
teins can inhibit invasion [19], it has also beenshown, however, that
there is differential expression of these proteins [20–22]. This results
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provides the parasite with the ability to evade antibody-mediated
immune mechanisms and to utilize those erythrocyte surface
proteins immediately present in the host blood cells. It is unlikely
that vaccines incorporating only a single blood-stage antigen will be
sufficient to provide adequate protection against the severity of the
disease seen in malaria endemic areas given the extensive diversity
of Plasmodium’s invasion repertoire and the variability of the human
immune response.
In an attempt to dissect out the invasion inhibitory effects of
antibodies against ligands from both the SA dependent and SA
independent pathways, we have used EBA-175 and RH5 as model
members of each pathway. EBA-175 binds to GPA for invasion of
erythrocytes, requiring both the sialic acid residues as well as the
peptide backbone of GPA for successful binding [10]. EBA-175
and other EBA family genes contain six extracellular regions, of
which only region II binds erythrocyte receptors [19,23]. Despite
the expression of this ligand by all P. falciparum clones, the effect of
antibodies to region II of EBA-175 on the invasion of erythrocytes
is variable [19,24–26]. EBA-175 is used by a wide variety of
parasite clones for invasion, and a recent paper [27] shows that
antibodies specific for EBA-175 block erythrocyte invasion
through the EBA-175/GPA pathway. The authors also reported
that inhibition of parasite invasion by antibodies to region II of
EBA-175 is not affected by polymorphisms occurring in region II.
RH5, while being the smallest member of the PfRH family at
65kDa, appears to have a critical role in invasion as attempts to
disrupt the gene have not been successful [2,28]. Unlike other
genes encoding merozoite surface proteins, such as Pfama1, there
have been few non-synonymous mutations observed so far in the
gene encoding PfRH5 [28], and there have been no reports to date
of any genetic diversity studies from natural parasite populations.
In this study, we analyzed the individual and combined effects of
antibodies against these two parasite ligands on invasion. Results
presented in this study validate the use of a combination of these
two ligands as a potential vaccine that would have broad activity
against P. falciparum.
Results
Antigen expression and testing for function
The members of the PfRH protein family have no obvious
domain structures, such as the region II cysteine-rich domains of
the EBL family. We therefore decided to use the entire PfRH5
protein as the immunogen as additionally, differing reports of
ability to inhibit parasite invasion were reported based on the
region of PfRH5 used for immunization [2,16,29]. It was also
important to determine that the recombinant proteins used for
immunization were conformationally similar to the native parasite
proteins. Thus, besides looking at the purity and stability of the
products, we also assessed the binding ability of these recombinant
proteins to erythrocytes. We chose to express RH5 in the wheat
germ system on account of the multiple advantages afforded by it.
It is a eukaryotic expression system that has no glycosylation
machinery, thus mimicking native Plasmodium antigen expression.
It can be established as a high-throughput platform (in 6 well
robotic formats), resulting in total yields of ,2 mg protein
overnight. There has been a high success rate of expression
reported in literature [30,31] from genome-wide malaria, human,
and plant projects. The successful expression of the full-length
recombinant RH5 (hereafter rRH5), produced by the wheat-germ
synthesis method was confirmed by the presence of a ,63 kDa
product on SDS-PAGE gel after elution of the total protein pre-
paration, as shown in Figure 1A, lane 1. This rRH5 antigen also
binds to normal erythrocytes: this was determined by loading the
eluate from the Ni column purification onto an SDS-PAGE gel,
the presence of where the expected a ,63 kDa was visible (see
Figures 1A, lane 2 and 1B). This confirms that this method of
expression was effective at producing a functionally conformed
antigen. As we propose that rRH5 would be a candidate to add to
the current EBA-175 vaccine regime, we have used the same sub-
fragment of the EBA-175 antigen encompassing region II
(EBA_175RII) that is being utilized in clinical trials (Figure 1C).
Thus, although correct expression of this recombinant has been
determined elsewhere [32], we also have independently deter-
mined its conformity by erythrocyte binding, resulting in the
expected ,80 kDa product, as shown in Figure 1D.
Anti-EBA-175RII and anti-rRH5 antibodies recognize
native parasite protein
Mice were immunized with full-length rRH5, or rEBA-175RII,
or a combination of both, and ascites and cardiac bleed sera were
obtained at the end of the immunization regimen. It is important
to ensure that the sera produced recognize and react with the
specific native parasite proteins to ensure any effect mediated by
antibodies contained therein is specific to the immunogen. There-
fore, all sera produced were assayed on both Western Blots of
parasite extracts as well as in IFAs on smears of mature stage
parasites. Immunoblotting with sera obtained on native parasite
Figure 1. Recombinant EBA-175 and RH5 antigens are stable,
pure and expressed in the correct conformation. The non-
reduced (Lane 1 of panel A) and the reduced elution (Lane 2 of panel A;
both visualized by Coomassie staining) of region II of EBA-175
synthesized using the yeast expression system Pichia pastoris, and the
binding of this recombinant to normal erythrocytes (panel B), confirm
correct expression and conformation of the EBA-175RII antigen with the
expected product of ,80 kDa (indicated by the arrows in Lane 2 of
panel A and panel B). The elution of full length RH5 synthesized using
the wheat-germ synthesis (panel C, indicated by the arrow), and
binding of rRH5 (panel D) to normal erythrocytes indicates functional
conformity of this recombinant antigen, as shown by the presence of a
single product at the expected size of ,63 kDa (indicated by arrows in
both C and D).
doi:10.1371/journal.pone.0030251.g001
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native EBA-175, as determined by the 175 kDa product on SDS-
PAGE gel (Figure 2A, lane 1). Immunoblotting with antibodies
against the rRH5 protein showed that these antibodies are also
specific for the native RH5 protein (Figure 2B). When sera from
mice immunized with the combination of the two antigens, both a
175 kDa product and the native RH5 protein of 65 kDa are
obtained (see Figure 2A, lane 2). The specificity of anti-EBA-
175RII and anti-rRH5 to native protein was independently con-
firmed by immunofluorescence, using FITC-conjugated anti-
mouse IgG and DAPI staining, and further confirmed that native
EBA-175 and RH5 are localized to the apical end of mero-
zoites, as expected for parasite proteins involved in invasion (see
Figures 2C–2D).
Confirmation that anti-EBA-175RII is effective at inhibiting
invasion of the parasite 3D7 isolate
After purifying the IgG fraction from the different sera, invasion
inhibition assays (IIAs) in 250 mL cultures were established with
total antibody concentrations ranging from 1.0 mg/mL to 500 mg/
mL. All cultures were initiated at 0.8% parasitaemia using mature
parasites (schizonts) purified off a Percoll gradient, and the
resulting parasitaemia after 24–30 hours (i.e. after only one round
of invasion) was determined. A dose-dependent curve of inhibition
was obtained using IgG from EBA-175RII immunized mice and
the degree of inhibition increased from 15%, at 1 mg/mL, to 84%,
500 mg/mL, compared to the no IgG control (Figure 3A). Inhibi-
tion assays performed with control IgG in this same range of
concentrations yielded 5.0% to 23% inhibition. This confirms the
specificity of the inhibition. However we observe a plateauing effect
at 250 mg/mL, when the effective inhibition reaches 77% inhibition
(see Figure 3A) and concentrations higher than this do not yield
significantly higher inhibition. Previous studies with antibodies
produced against the same EBA-175RII antigen in rabbits have
shown up to ,80% growth inhibition [32,33], suggesting that this
antigen is an effective immunogen, and provides encouragement for
continuing with this antigen in human studies. Of note how-
ever, when this same EBA-175RII antigen was used to immunize
Figure 2. Recognition of native proteins. Anti-EBA-175RII antibodies are able to detect native EBA-175 protein of 175 kDa from 3D7 parasite
lysates (Lane 1, panel A). Anti-EBA-175RII/rRH5 (sera from the combined vaccine) is able to detect both EBA-175 and RH5 native proteins from the
same lysate (Lane 2, panel A; EBA-175 indicated by top arrow; RH5 indicated by bottom arrow). Anti-rRH5 antibodies are specific for the native
65 kDa RH5 protein from 3D7 parasite lysate (panel B; indicated by arrow). All products were visualized with ECL after immunoblotting.
Immunofluorescent detection of EBA-175 and RH5 in mature and rupturing 3D7 schizonts. Parasites were labelled with anti-EBA-175RII (panel C)o r
with anti-rRH5 (panel D) at dilutions of 1:100 and 1:500, then the slides were incubated with FITC-conjugated anti-mouse IgG (green) and mounted
with 10 mg/mL DAPI (blue). EBA-175 and RH5 are each localised to the apical end of merozoites. Non-staining with preimmune sera (1:100 dilution)
confirm specificity of each antibody to its respective antigen.
doi:10.1371/journal.pone.0030251.g002
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observed (10–20%) despite high antibody titers [34], suggesting the
need for additional components in an invasion targeting vaccine.
Anti-rRH5 antibodies exert potent anti-invasion effects in
3D7
This is the first study to test the effect of antibodies against full-
length rRH5 on invasion of P. falciparum, and we obtained potent
degrees of invasion inhibition ranging from 20% at 1.0 mg/mL, to
a maximum of 72% at 250–500 mg/mL (Figure 3B). There is no
difference in the levels of inhibition obtained from anti-rRH5 or
anti-EBA-175RII between 1 mg/mL and 50 mg/mL, although, at
the higher concentrations (100 mg/mL to 500 mg/mL), the level of
inhibition from anti-EBA-175RII does exceed that of anti-rRH5
(P,0.05, T-test). These data are the first to indicate that PfRH5
alone is an effective immunogen, capable of eliciting an effective
inhibitory immune response in these mice.
Combination anti-EBA-175RII and rRH5 antibodies show
synergistic effects at the lower end of the concentration
range
Apart from determining the inhibitory effects of antibodies to
full-length RH5, the other purpose of this study was to look for
synergistic effects on inhibition of invasion in the presence of
antibodies to both EBA-175 and RH5, in order to block multiple
ligands required for merozoite invasion simultaneously, thereby
overcoming functional redundancy among invasion ligands and
the capacity for immune evasion. Thus, IIAs were performed with
two combination variants: anti-EBA-175RII/rRH5 (obtained from
immunizing mice with a single vaccine containing equal quantities
of each antigen) and an artificial in-tube combination of the two
IgGs after purification. This second combination used equal
quantities of purified IgG from each individual serum, with 50% of
the total IgG concentration coming from each antibody. As
expected, there is a linear increase in invasion inhibition directly
correlated to the increase in antibody concentration for both types
of combination, and there is no significant difference between the
level of inhibition obtained from these two types of combinations
at any concentration (P.0.05, T-test; Figure 3C).
Interestingly, we observe two patterns of inhibition at the
different ends of the concentration spectrum. At the lower
concentrations of antibody (1.0 mg/mL – 5.0 mg/mL) we obtain
a synergistic effect with the combination IgG a as these antibodies
exert a greater inhibition on invasion than antibodies from the
single immunogen sera used at the same concentration: 31% and
28% inhibition for the anti-EBA-175RII/rRH5 and anti-EBA-
175RII+anti-rRH5, respectively, compared to 15% and 20%
inhibition from the single anti-EBA-175RII and anti-rRH5 IgG,
respectively (P,0.05, T-test for anti-EBA-175 vs. either combina-
tion; see Figure 4). As the concentration of antibody used in the
IIA increases, however, this synergy is replaced by a different type
of inhibitory profile where we obtain intermediate levels of
inhibition to that observed for the single antibodies. Thus, at these
concentrations (250 mg/mL to 500 mg/mL), the level of inhibition
is equivalent to 50% contribution from anti-EBA-175RII plus 50%
from anti-rRH5, suggesting that the individual components are
acting independently to each other. At 100 mg/mL, the level of
inhibition from each combination is only as great as anti-EBA-175,
indicating that around 100 mg/mL, there is a transition from a
synergistic effect to an independent effect. It is possible that when
both antibodies are present and in excess, any synergistic effect is
masked by some steric hindrance. If so, this would mean it is
possible that as an individual antibody binds to its specific antigen,
it creates a physical block for the other antibody to reach its
antigen, thus the antigen is still available for binding to its
erythrocyte receptor for invasion. We are currently investigating
underlying mechanisms that could form the basis of this transition.
Of interest to vaccine design and deployment, current studies
indicate that titers of antibodies in vaccinated people would
approximate the lower end of the concentration spectrum [34]
and thus synergistic effects of antibodies from such combination
vaccines would be expected to be obtained.
Figure 3. Invasion Inhibition of 3D7 with anti-EBA-175RII and
anti-rRH5 antibodies. Anti-EBA-175RII (solid black line in panel A) and
anti-rRH5 antibodies (solid blue line in panel B) inhibit invasion of 3D7
in a linear correlation to a similar extent. The two varying combinations
used, anti-EBA-175RII/anti-rRH5 and anti-EBA-175RII+anti-rRH5 (solid red
and solid green lines, respectively, in C), also showed the same positive
correlation between increased antibody concentration and % inhibition
(the color key for each antibody is conserved from A, B, and C).
Percentage invasion inhibition from purified mouse IgG used as a
control is shown as dashed black line (A, B, C).
doi:10.1371/journal.pone.0030251.g003
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treated erythrocytes confirms SA dependence of EBA-175
and SA independence of RH5
Treatment of erythrocytes with enzymes that selectively cleave
moieties of malarial receptors would result in elimination of the
use of that specific invasion pathway. We thus decided on the use
of neuraminidase (Nm) that removes sialic acid residues from red
cell receptors, such as GPA, the EBA-175 receptor. We reasoned
this would eliminate the EBA-175 contribution to the invasion
arsenal as its cognate receptor was impaired. Our hypothesis was
confirmed when the invasion inhibition that was obtained in
untreated erythrocytes in the presence of anti-EBA-175RII IgG
effectively disappeared when Nm-treated cells were used in the
invasion assay (Figure 5A). PfRH5, on the other hand, is known to
bind to a non-sialylated receptor [2,16,28,29] and thus, as
expected, we obtained a minimal difference in the invasion
inhibition effect from anti-rRH5 between untreated and Nm-
treated erythrocytes (Figure 5B). When the antigen combinations
are used with Nm-treated cells, the expectation is that any invasion
inhibition observed could only be from the action of the anti-rRH5
portion of the antibodies (the anti-EBA-175RII portion being
blocked by the enzymatic treatment), and this is observed in the
second combination when the independent antibodies are combined
after purification: the invasion inhibition is reduced by ,60% from
46% in untreated cells to 28% in Nm-treated cells (Figure 5C). These
data confirm that RH5 utilizes a SA independent pathway for
invasion, as previously shown [16], and when the EBA-175/GPA
pathway is blocked, 3D7 parasites will utilize this alternative, SA
independent, pathway for invasion. However, there is no significant
decrease from the anti-EBA-175RII/rRH5 combination as expected
(Figure 5C). This suggested that the RH5 portion of the combination
vaccine was perhaps more immunogenic than the EBA-175RII
component in these mice. However, titrating the sera against
recombinant EBA-175RII and recombinant RH5 showed that both
serahadapproximatelythesametiters(,1:100,000, data not shown).
Future work will be directed to understand this discrepancy between
the two combinations.
Alternative pathways are used by the parasite for
invasion
Different parasite strains use different erythrocyte receptors for
invasion, such that some strains are totally dependent upon a
Figure 4. Anti-sera against the hybrid vaccine show synergistic
effects at low concentrations. The invasion inhibition of both
combination sera are greater than those obtained from the individual
sera at the lowest concentrations used, 1 mg/mL. The combinations
contain 50% of each individual immunogen (in the case of the
combination vaccination, anti-EBA-175RII/rRH5) or sera (in the case of
the in-tube combination, anti-EBA-175RII+anti-rRH5). However, by
100 mg/mL, the synergistic effects of the combinations are no longer
apparent, and the inhibition from the combinations is equivalent to
,50% contribution from the two individual sera (anti-EBA-175RII shown
by black bars, anti-rRH5 shown by blue bars, anti-EBA-175RII/rRH5
shown by red bars, anti-EBA-175RII+anti-rRH5 shown by green, control
IgG shown by white bars).
doi:10.1371/journal.pone.0030251.g004
Figure 5. Enzymatic (neuraminidase) treatment of erythrocytes
eliminates the inhibitory effects of anti-EBA-175RII antibodies
but has only a mild effect on anti-rRH5 sera. Invasion inhibition
assays with 3D7 and neuraminidase-treated cells (100 mg/mL antibody
used) show that any inhibition due to the presence of anti-EBA-175RII
antibodies is masked by the removal of ligands with sialic acid
compared to untreated cells (A; anti-EBA-175RII and IgG shown as solid
black and solid white bars, respectively). Anti-rRH5 alone (B; solid blue
bars), or in combination (C; anti-EBA-175RII/rRH5 and anti-EBA-
175RII+anti-rRH5 shown as solid red and solid green bars, respectively)
is still able to significantly inhibit growth in treated cells as a sialic acid
independent pathway is utilized by the RH5 antigen.
doi:10.1371/journal.pone.0030251.g005
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multiple routes of invasion. It will be necessary that a malaria
vaccine target all these different parasite strains. We thus decided
to run the IIAs with the same set of sera on a parasite strain that
has a very different invasion profile from 3D7 (SA independent).
We chose Dd2 as it has been shown to be totally dependent upon
GPA for invasion such that Nm-treatment of erythrocytes results
in 100% inhibition of invasion in this strain [20], and the EBA-
175/GPA pathway has been presumed to be the dominant SA
dependent route of entry in this strain. Thus, we expected a high
inhibition of invasion with Dd2 in untreated erythrocytes when
anti-EBA-175RII antibodies are present: these antibodies will block
the native EBA-175 antigen, preventing the EBA-175/GPA
pathway required for invasion, mimicking the effect of Nm-
treatment on erythrocytes. However, we observed no more than
,60% inhibition of invasion (at 100 mg/mL; Figure 6A). Although
this is significantly greater than the inhibition seen with 3D7 at the
same antibody concentration (P=0.015, T-test), this is not a
complete block as seen when Dd2 invasion is assayed in Nm-
treated cells [35,36]. These results suggest that, contrary to
published reports, alternative SA dependent pathways (i.e.EBL-1/
GPB, EBA-140/GPC) are being utilized in Dd2 when the EBA-
175/GPA pathway is not available. Further investigation using
alternative SA dependent strains, such as W2-mef, are needed to
elucidate this apparent paradigm. The inhibition profile when
anti-rRH5 antibodies were used in the invasion assay are similar to
those obtained with anti-EBA-175RII in that the level of inhibition
at 50 mg/mL was equivalent to that of 3D7 (43% in Dd2,
compared to 41% in 3D7; see Figure 6B). However, at 100 mg/
mL, the inhibition observed was significantly higher in Dd2 than
3D7 (57% compared to 40%, respectively; P=0.003, T-test).
Interestingly, there was no difference in level of inhibition between
the two strains for the anti-EBA-175RII/rRH5 combination
(antibodies from a combined vaccination) at either concentration
(Figure 6C) but the level of inhibition observed in the presence of
the anti-EBA-175RII+anti-rRH5 (antibodies combined after puri-
fication) was significantly higher in Dd2 at both concentrations
(P,0.02, T-test).
Discussion
To control and eventually eradicate malaria, an effective
vaccine is considered to be necessary, in addition to currently
existing tools, such as drugs and insecticide treated nets. The main
requirement for the development of a successful anti-invasion
malaria vaccine is the demonstration that antibodies made against
each ligand can block the erythrocyte invasion of parasites. An in
vitro parasite invasion inhibition assay (IIA) is one of the widely-
used assays that can measure the functional activity of antibodies
against asexual erythrocyte stages of Plasmodium. While it is still
controversial whether the inhibitory activity measured by the IIAs
reflects protective immunity induced by a malaria vaccine, the
assay has been used in multiple preclinical and clinical studies as a
prime immunological readout [27,37] and we have used it in this
study to look at relative efficacy of two invasion ligands alone and
in combination to elicit inhibitory antibodies.
EBA-175, specifically region II of this antigen, is currently a
leading anti-malarial vaccine candidate, and EBA-175RII has been
shown to be safe and immunogenic in malaria-naı ¨ve adults
[34,38]. Further, the anti-sera from these vaccinated individuals
inhibit, but do not eliminate, the growth P. falciparum, suggesting
that additional components to the vaccine may be needed. As P.
falciparum has been shown to invade erythrocytes by multiple
pathways, using both the EBL and PfRH families a vaccine that is
able to target more than one pathway is desirable. Recent studies
have shown that the members of the EBL and PfRH families act
cooperatively in merozoite invasion [37] and this has important
implications for vaccine development. We chose to test EBA-175
in combination with PfRH5 as researchers have so far been unable
to produce a PfRH5-knock-out, suggesting that this antigen is
Figure 6. Dd2 parasites are not wholly dependent on the EBA-
175/GPA pathway of invasion. In the presence of anti-EBA-175RII
antibodies (A; black bars), inhibition when using the Dd2 strain is only
60% (Ab concentration of100 mg/mL), compared to 55% inhibition from
3D7, suggesting alternative SA dependent pathways are utilized by
Dd2, such as EBL-1/GPB or EBA-140/GPC (for A, B and C, Dd2 with its
control IgG shown as solid white bars). Although anti-rRH5 antibodies
(B; blue bars), should only block a SA independent pathway, there is still
greater inhibition with Dd2 compared to 3D7. In the presence of both
antibodies (C; anti-EBA-175RII/rRH5 shown as red bars and anti-EBA-
175RII+anti-rRH5 shown as green bars, respectively), there is a significant
difference in the ability of Dd2 to invade compared to 3D7, especially
when individual antibodies are combined.
doi:10.1371/journal.pone.0030251.g006
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mixed success with inducing invasion inhibitory antibodies that
could be ascribed to the use of different regions of RH5 as
immunogen [16,28,29]. So far, no studies have been done with
full-length RH5 and to ensure a thorough validation of this ligand
as a vaccine candidate, we undertook to assess the functionality
and immunogenicity of the full-length RH5 protein alone and in
conjunction with EBA-175RII.
The rationale for including EBA-175RII in a multi-component
vaccine has been well established by previous studies and these
have shown that not only does this antigen elicit a suitable immune
response, but anti-EBA-175RII antibodies are able to inhibit
invasion of merozoites into erythrocytes by blocking the specific,
SA dependent, EBA-175/GPA pathway [33] but by also inhibiting
an alternative, SA independent, pathway [24,39]. Further, both
the DNA and recombinant protein forms of the EBA-175RII
vaccine component have been found to be safe and immunogenic
in animal models and malaria-naı ¨ve human trials, respectively
[25,26,34].
Our results with mouse anti-EBA-175RII antibodies show
similar invasion inhibition in both 3D7 and Dd2 parasite strains
and confirm the vaccine potential of this malarial ligand. A
surprising find was that anti-EBA-175RII antibodies did not totally
eliminate invasion of Dd2 as seen in its invasion of neuraminidase
treated cells. The EBA-175/GPA pathway is thought to be the
predominant route of entry for SA dependent parasite strains but
this study shows that efficient invasion persists for this strain in the
presence of potent anti-EBA-175 antibodies. Thus, other SA
dependent pathways, EBL-1/GPB and EBA-140/GPC may be
operating to overcome the loss of the GPA mediated pathway.
Selection for these alternative ligand mediated pathways was not
needed over time as was seen in the creation of the Dd2-Nm strain
[35,36]. Further molecular analysis of gene expression of parasites
in these IIA assays may shed light on the identity of these parasite
ligands.
This is the first study to characterize the antibodies generated to
full length RH5 and we report that the invasion-inhibitory
potential of these antibodies equals that generated by EBA-175RII
for both 3D7 and Dd2 parasites. Purified anti-rRH5 immuno-
globulins recognized the native parasite ligand and inhibited
merozoite invasion in a dose-dependent manner resulting in up to
72% inhibition at 500 mg/ml. These results indicate a possible
reason for the inability to successfully delete the gene encoding
RH5 from the parasite genome and stress the importance of
determining the candidacy of the various EBL and RH ligands in
such IIAs before designing rational vaccine combinations that will
induce immune responses that ultimately may disrupt merozoite
invasion.
The most interesting outcome of this study was the dual effect
seen with the hybrid EBA-175RII/rRH5 immunogen at either end
of the concentration spectrum. The lower concentrations of
antibody yielded the desirable ‘‘synergy effect’’ with the combi-
nation antigen inhibiting parasite invasion more efficiently than
the individual components (additive effect). This effect dissipates at
,100 mg/ml and transitions to an inhibition profile that resembles
a profile where each antibody seems to act independently (by 250
and 500 mg/ml), and the inhibition we obtain parallels that of the
most active component. To understand this dual effect we have
come up with a model that explains the outcomes based on
whether the ligands (EBA-175 and RH5) act independently of
each other or co-operatively. It would appear that when antibody
is present at lower concentrations, the lack of steric hindrance
allows the antibodies to exert an additive inhibitory effect
(Figures 4 and 7). However, as the antibody concentration rises,
the antibody against EBA-175 (the EBA-175 ligand is present in
higher amounts than RH5 and also comes into contact with the
red cell earlier (Ord et al, unpublished observations) saturates the
surface of the erythrocyte not allowing anti-RH5 to mediate an
effective inhibitory response (Figure 7). Thus, at higher concen-
trations of the combo antibody what is apparent in the IIA is only
the inhibitory effect of anti-EBA-175RII IgG. This steric hindrance
model may explain why the synergy seen with the hybrid
immunogen at low concentrations disappears mid-range.
From the human vaccine point of view, this data is quite
encouraging, as realistic titers from current human trials [34]
indicate that they would approach the lower end of the IIA
concentration spectrum used in this study. Thus, in the event of
multiple antigen immunizations, synergistic effects among the
antibodies to yield potent inhibitory effects on merozoite invasion
may actually be the desirable outcome.
Methods
Ethics statement
All animal work in this study was carried out at A&G
Pharmaceutical, Columbia, MD. The A&G Institutional Animal
Care and Use Commitee reviewed and approved the animal
protocols (protocol number AG-01) to ensure they met with strict
accordance to the recommendations of the Guide for the Care and
Use of Laboratory Animals of the NIH, and with accordance to
the PHS Policy at A&G Pharmaceutical (OLAW AWA #A4404-
01). Isoflurane was used to sedate the mice for immunizations, and
all efforts were made to minimize suffering at all times.
Parasite culture
P. falciparum 3D7 and Dd2 lines were obtained from the Malaria
Research and Reference Reagent Resource Center (MR4) and
cultured in human type A+ erythrocytes as described [40]. The
identity of each strain has been confirmed by microsatellite
fingerprinting [41].
Recombinant protein synthesis
Region II of the EBA-175 protein was synthesized by Cambrex
Biosciences Inc., as described [34,42]. Full-length RH5 was
produced by the wheat germ cell-free system (CellFree Sciences,
Matsuyama, Japan) as described elsewhere [30,43]. Briefly, the
full-length RH5 [comprising amino acid (aa) 26Glu to aa 526Gln of
the 3D7 sequence without signal peptide, Met at N-terminus, and
a hexa-histidine (HIS) tag at C-terminus] was cloned into the
wheat germ cell-free expression vector, pEU-E01-MCS (CellFree
Sciences) at XhoI/NotI sites. The recombinant RH5 protein,
,63 kDa with HIS-tag, was expressed using wheat germ cell-free
system (CellFree Sciences) and purified using Nickel-Sepharose
column (GE Healthcare, Camarillo, CA) as described previously
[31].
Mouse immunizations/antibody production &
purification
Balb/c mice in groups of 5, received one primary immunization
and three boosts over a period of 2 months with either EBA-175RII
alone, rRH5 alone, or an equal combination of both. Precision
Antibody Proprietary Technology was used for all the immuni-
zations. Ascites and cardiac bleed sera were obtained from all
three regimes and pre-immune sera was collected from non-
immunized mice. The IgG fraction from ascites sera were purified
using Protein G sepharose beads (GE Healthcare) and dialyzed
against 1x PBS overnight.
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The recombinant EBA-175RII and RH5 proteins were incu-
bated with type A+ erythrocytes for 2 hr at room temperature.
Erythrocytes were then washed with RPMI 1640 incomplete
medium, layered over dibutylsulphate oil (Sigma), and centrifuged
at 6,000 x g for 1 min. The supernatant and oil were removed by
aspiration. Bound parasite proteins were eluted from the
erythrocytes with 1.5 M NaCl and the eluate was used for
immunoprecipitation/Western Blotting with 10 mg purified anti-
EBA-175RII or anti-rRH5 antibodies.
Immunoprecipitation/Western blotting
Saponin-lysed pellets from mature-stage parasites, or lysate
obtained from erythrocyte binding assays, were separated under
reducing conditions with either 6% or 10% SDS-PAGE gels, as
appropriate. Anti-EBA-175RII or anti-rRH5, along with appro-
priate secondary antibodies, were used to detect specific immuno-
reactivity. Mouse pre-immune sera was used as a control.
Immunofluorescence Assay (IFAs)
Mature schizont stage 3D7 parasites were smeared onto slides
and stored at 270uC. Slides were thawed, fixed with 10%
methanol/90% acetone for 20 min at room temperature. After
air-drying, the smears were blocked and then incubated at room
temperature for 1 hr with serum containing the anti-EBA-175RII,
anti-rRH5 or anti-EBA-175RII/rRH5 antibodies, and then
incubated with FITC-conjugated anti-mouse antibody (1:100) for
1 hr at room temperature protected from light. All slides were
mounted using 10 mg/mL DAPI and observed under UV light.
Images were merged using Adobe Photoshop Elements 6.0
software.
Neuraminidase treatment of erythrocytes
Cells were treated with 0.025 U/mL neuraminidase (Vibrio
cholerae; Roche), at 37uC for 1 hr. The efficacy of each enzyme
treatment was assessed in the Laboratory of Immunohematology,
New York Blood Center, by assaying for loss of erythrocyte
agglutinability, using a panel of monoclonal antibodies against
suitable antigenic determinants on different blood group proteins.
Invasion inhibition assays (IIAs)
Mature trophozoite stages were isolated on 40%/70%/90%
Percoll gradients as previously described [44]. Cultures for IIAs
were established using a starting parasitaemia of 0.8% for 3D7 and
0.6% for Dd2, at a 5% haematocrit. Purified anti-EBA-175RII,
anti-rRH5, and combination anti-EBA-175RII/anti-rRH5 anti-
bodies were tested independently using 3D7 and IgG dilutions
ranging from 1.0 mg/mL to 500 mg/mL. A second combination
was also tested: equal proportions of anti-EBA-175RII IgG and
anti-rRH5 IgG were combined together after purification and
Figure 7. Independent Antibody Interaction and Co-Operative Antibody Interaction Models. Independent Antibody Interaction Model
(Panel A): If the ligand-receptor interactions are independent of each other, invasion by either EBA-175 (Route 1) or by RH5 (Route 2) is not affected by
the other. Thus, in the presence of both anti-EBA-175RII and anti-rRH5 antibodies, the expected inhibition from the combination anti-sera is ADDITIVE
(synergistic) when compared to the inhibition from the individual anti-sera. Co-Operative Antibody Interaction Model (Panel B): If the ligand-receptors
act in a co-operative method, then invasion by EBA-175 (Route 1) and RH5 (Route 2) are not independent of each other. Thus, in the presence of anti-
EBA-175RII and anti-rRH5 antibodies, the expected inhibition from the combination anti-sera is only as effective as the most active individual antibody.
Antibody Steric Hindrance (Panels C and D): Data suggests that EBA-175 abundance is greater than RH5 and is possibly released before RH5 (Ord et al,
unpublished observations). At LOW antibody concentrations (C), there is no possible hindrance of RH5 by EBA-175, and all available antibodies are able
to bind to their respective ligands independently. This is observed as growth inhibition with the combination anti-sera being more effective than that
observed with the individual antibodies, i.e., it follows the Independent Antibody Interaction Model (A). Conversely, at HIGH antibody concentrations
(D),anti-EBA-175antibodiesareabletobindtoavailableEBA-175ligandsbut theystericallyhindersomeRH5antibody/ligandinteractions,leavingsome
RH5ligands availableforinvasionthroughtheRH5ligand/receptorpathways.Thisisobservedasgrowthinhibitionwiththecombinationanti-serabeing
only as effective as anti-EBA-175RII sera alone, i.e. it follows the Co-Operative Antibody Interaction Model (B).
doi:10.1371/journal.pone.0030251.g007
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IgG from mouse sera (Sigma) was used at equivalent concentrations
as negative controls. IIAs with Dd2 were performed at antibody
concentrations of 1.0, to 100 mg/mL. IIAs at 100 mg/mL and
250 mg/mL with3D7 were also performed on erythrocytes that had
been treated with neuraminidase. All IIAs were assessed after 24–30
hr by enumerating infected erythrocytes on Giemsa stained smears.
All IIAs were performed at least 3 times and the representative
results from one such assay is shown in the figure.
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